Therapeutic and Technology Expertise and Due Diligence
THERAPEUTIC AND TECHNOLOGY BREADTH
Locust Walk has completed engagements across a range of therapeutic areas and modalities at various stages of development. We have extensive experience in partnering and financing within oncology, neuroscience, immunology, rare diseases, and beyond, encompassing, biologics, small molecules, genetic medicine, cell therapy, and more. Our in-depth analysis of the science and narrative ensures that our clients have distinctive approaches capable of attracting partners and investors.
Due Diligence Process
Locust Walk leverages proprietary market insights to drive transactions and optimize strategy. Our entire deal team has science degrees and/or extensive scientific experience to thoroughly analyze relevant programs. Additionally, we engage external experts, including investors and strategic partners, alongside our scientific advisory board and Key Opinion Leader network.
As part of our pre-engagement process for at-risk sell-side and financing mandates, our internal due diligence committee and external scientific advisory board conduct thorough diligence. The committee, composed of non-client-facing deal team members, ensures an independent assessment of the science.
This process typically takes one to two weeks, during which we review the confidential presentation, contact log, and virtual data room accessed by partners and investors. We also consult our scientific advisory board and, when necessary, external experts, including anonymous inquiries to partners and investors.
Once due diligence is complete, we make a full commitment. If we choose not to engage, we provide clear feedback on our rationale. Engagement economics are usually discussed concurrently to ensure alignment.
Extensive Global Network of Key Decisionmakers
We maintain a robust digital repository of:
150+ Most Active
Life Science Investors
Information on investor
funding preferences, current
portfolio priorities, portfolio
company status, and types of
investors across stages.
funding preferences, current
portfolio priorities, portfolio
company status, and types of
investors across stages.
50+ Most Active Licensors/Acquirers
Insights into what buyers
want, including development
stage, therapeutic area,
technology, commercial
potential, and externalization preferences.
want, including development
stage, therapeutic area,
technology, commercial
potential, and externalization preferences.
100s of other Public/ Private Biotechs
Dealflow sources, willingness
to transact, and types of
transactions considered
(global vs. regional, asset vs. platform).
to transact, and types of
transactions considered
(global vs. regional, asset vs. platform).
Academics and
Key Opinion Leaders
Trends of scientific interest,
novel modalities, targets or
technologies, and program
viability based on data.
novel modalities, targets or
technologies, and program
viability based on data.
